Medicamen Biotech, a company in the Pharmaceuticals industry, reported revenue of ₹55 crore and net profit of ₹4.12 crore for the September 2026 quarter.
Medicamen Biotech (NSE: MEDICAMEQ-BE) closed at ₹285.90 on 20 Nov 2026. Its market capitalisation is ₹402 crore and it trades at 34.7 times earnings.
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.